atezolizumab/tiragolumab (RO7538483) / Roche - LARVOL DELTA

SKYSCRAPER-11: A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid Tumors (clinicaltrials.gov) - P2 | N=60 | Active, not recruiting | Sponsor: Hoffmann-La Roche | Trial completion date: Sep 2025 ➔ Dec 2025 | Trial primary completion date: Sep 2025 ➔ Dec 2025

Trial completion date • Trial primary completion date • Solid Tumor

SKYSCRAPER-11: A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid Tumors (clinicaltrials.gov) - P2 | N=60 | Active, not recruiting | Sponsor: Hoffmann-La Roche | Recruiting ➔ Active, not recruiting

Enrollment closed • Solid Tumor

SKYSCRAPER-11: A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid Tumors (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: Hoffmann-La Roche | Trial completion date: Feb 2025 ➔ Sep 2025 | Trial primary completion date: Feb 2025 ➔ Sep 2025

Metastases • Trial completion date • Trial primary completion date • Oncology • Solid Tumor